Lexicon Pharmaceuticals names Dr. Pablo Lapuerta CMO

Tuesday, March 29, 2011 12:15 PM

Lexicon Pharmaceuticals has named Pablo Lapuerta, M.D., chief medical officer. He will be responsible for directing clinical development of Lexicon's drug candidates from phase II proof-of-concept through phase III and approval.

Dr. Lapuerta has 15 years of pharmaceutical industry experience including leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas. Most recently, Lapuerta served as vice president at Bristol-Myers Squibb, where he was responsible for global development of an Alzheimer's disease drug candidate.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs